BLOODY SEMINAR 29.1.2026

16:15–16:40 Coffee and exhibition (sponsors GSK and Sobi)

16:40-16:45 Welcome, Chair of the Foundation’s Board, Prof. Riitta Lassila

16:45-17:45 ASH2025 presentations (10min each), moderator Riitta Lassila

Heikki Kuusanmäki (ASH): High Throughput Multiparameter Flow Cytometry and Intra-Leukemia Heterogeneity in Drug Response

Sadiksha Adhikari (ASH): Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia

Aino-Elina Häkkinen(ASH):  Tracing the evolution of clonal T cell responses in LGL leukemia with single-cell whole genome sequencing

Sofia Forstén (ASH): Anti-TIM3 with hypomethylating agent revives NK and cytotoxic CD4+ T cell activity in patients with AML or MDS

Eva Daniela Mendoza Ortiz (ASH): Efficacy of the JAK2/FLT3 inhibitor pacritinib in NPM1 mutated Acute Myeloid Leukemia

17:45–18:00 Coffee and exhibition (sponsors GSK and Sobi)

18:00-18:40 ASH25/EHA25/ISTH presentations (10min each), moderator Olli Lohi

Selma Sorri (ASH): Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy

Marja Hakkarainen (EHA): Hematopoietic stem cell transplantation for ERCC6L2 disease

Mika Kontro (ASH): Updated results from the bexmab Phase 1/2 study

Riitta Lassila (ISTH): Highlights of ISTH2025

18:40-19:00 The Best from ASH2025 – by GSK

19.00 Closing remarks